The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab

Shu-Dong Zhang; Cian M. McCrudden; Meng Chen; Yao Lin; Hang Fai Kwok

doi:10.2147/OTT.S80518

The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab

Shu-Dong Zhang
, Cian M. McCrudden
, Meng Chen
, Yao Lin
, Hang Fai Kwok

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

154 Downloads (Pure)

Original language	English
Pages (from-to)	835
Journal	OncoTargets and Therapy
Volume	8
DOIs	https://doi.org/10.2147/OTT.S80518
Publication status	Published (in print/issue) - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

colon cancer
VEGFA
FLT1
KDR
angiogenesis
survival

Access to Document

10.2147/OTT.S80518

2015-OTT-80518-vegfa-colon-041515Final published version, 1.17 MB

Cite this

@article{86495642565243bb8e33545bc43e322d,

title = "The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab",

keywords = "colon cancer, VEGFA, FLT1, KDR, angiogenesis, survival",

author = "Shu-Dong Zhang and McCrudden, \{Cian M.\} and Meng Chen and Yao Lin and Kwok, \{Hang Fai\}",

year = "2015",

doi = "10.2147/OTT.S80518",

language = "English",

volume = "8",

pages = "835",

journal = "OncoTargets and Therapy",

issn = "1178-6930",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab

AU - Zhang, Shu-Dong

AU - McCrudden, Cian M.

AU - Chen, Meng

AU - Lin, Yao

AU - Kwok, Hang Fai

PY - 2015

Y1 - 2015

KW - colon cancer

KW - VEGFA

KW - FLT1

KW - KDR

KW - angiogenesis

KW - survival

U2 - 10.2147/OTT.S80518

DO - 10.2147/OTT.S80518

M3 - Article

SN - 1178-6930

VL - 8

SP - 835

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

ER -